The research of Dr. Sévigny’s team focusses on the functions of extracellular nucleotides, exerted through the activation of P2 receptors, with an emphasis on the enzymes that regulate their concentrations at the cell surface.  Dr. Sévigny and his team have also identified, cloned and characterized six new genes, including the first member of a new family encoding enzymes called NTPDases.  His team is interested in several biological functions including the regulation of inflammation in response to pathogenic determinants, the migration of immune cells, the functions of leukocytes, the contraction of smooth muscles, and in particular the regulation of inflammation of the intestine with an emphasis on epithelial cells and on a potential treatment for inflammatory bowel disease.

Dr Sévigny’s team uses animal models with KO mice as well as methods of cell biology (murine and human primary cells), pharmacology, biochemistry and immunology.

CHUL
2705, boulevard Laurier
T1-49
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 46319
+1 418-654-2765
jean.sevigny@crchudequebe...

Latest news

290 entries « ‹ 2 of 29 › »

Begum Z, Ullah S, Akram M, Uzair M, Ullah F, Ahsanullah , Pelletier J, Sévigny J, Iqbal J, Hassan A

Identification of thienopyrimidine glycinates as selective inhibitors for h-NTPDases

Journal Article

Bioorg Chem, 129 , 2022.

Abstract | Links:

Jung YH, Shah Q, Lewicki SA, Pramanik A, Gopinatth V, Pelletier J, Sévigny J, Iqbal J, Jacobson KA

Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists

Journal Article

Bioorg Med Chem Lett, 75 , 2022.

Abstract | Links:

Schäkel L, Mirza S, Winzer R, Lopez V, Idris R, Al-Hroub H, Pelletier J, Sévigny J, Tolosa E, Müller CE

Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy

Journal Article

J Immunother Cancer, 10 (8), 2022.

Abstract | Links:

Ullah S, Pelletier J, Sévigny J, Iqbal J

Synthesis and Biological Evaluation of Arylamide Sulphonate Derivatives as Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 and -3 Inhibitors

Journal Article

ACS Omega, 7 (30), 2022.

Abstract | Links:

Alvarez CL, Chêne A, Semblat JP, Gamain B, Lapouméroulie C, Fader CM, Hattab C, Sévigny J, Denis MFL, Lauri N, Ostuni MA, Schwarzbaum PJ

Homeostasis of extracellular ATP in uninfected RBCs from a Plasmodium falciparum culture and derived microparticles

Journal Article

Biochim Biophys Acta Biomembr, 1864 (10), 2022.

Abstract | Links:

Hamoudi C, Zhao C, Abderrazak A, Salem M, Fortin PR, Sévigny J, Aoudjit F

The Purinergic Receptor P2X4 Promotes Th17 Activation and the Development of Arthritis

Journal Article

J Immunol, 208 (5), 2022.

Abstract | Links:

Abbas S, Afzal S, Nadeem H, Hussain D, Langer P, Sévigny J, Ashraf Z, Iqbal J

Synthesis, characterization and biological evaluation of thiadiazole amide derivatives as nucleoside triphosphate diphosphohydrolases (NTPDases) inhibitors

Journal Article

Bioorg Chem, 118 , 2022.

Abstract | Links:

Salem M, Lecka J, Pelletier J, Gomes Marconato D, Dumas A, Vallières L, Brochu G, Robaye B, Jobin C, Sévigny J

NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD

Journal Article

Gut, 71 (1), 2022.

Abstract | Links:

Schäkel L, Mirza S, Pietsch M, Lee SY, Keuler T, Sylvester K, Pelletier J, Sévigny J, Pillaiyar T, Namasivayam V, Gütschow M, Müller CE

2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors

Journal Article

Arch Pharm (Weinheim), 354 (12), 2021.

Abstract | Links:

Iqbal J, Jacob C, Sévigny J

Editorial: Metalloenzymes: Potential Drug Targets

Journal Article

Front Pharmacol, 12 , 2021.

| Links:

290 entries « ‹ 2 of 29 › »
Signaler des ajouts ou des modifications

Active projects

  • A recombinant soluble NTPDase8 as a novel biological treatment for inflammatory bowel disease, from 2021-10-01 to 2026-09-30
  • Ectonucleotidases and Extracellular Nucleotides in Smooth Muscle Cell Contraction, from 2023-04-01 to 2028-03-31
  • Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2024-06-30

Recently finished projects

  • A novel approach to treating inflammatory bowel diseases through the blocking of P2Y6 receptors, from 2018-04-01 to 2023-03-31
  • Role of NTPDase1 and Extracellular Nucleotides in Smooth Muscle Cell Contraction., from 2016-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery